Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.7
4.7
Journals
Biomedicines
Special Issues
Therapeutic Antibodies against Infectious Diseases
share announcement

Therapeutic Antibodies against Infectious Diseases

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".

Deadline for manuscript submissions: 30 September 2024 | Viewed by 2335

Special Issue Editor

Dr. Hugues Fausther-Bovendo

E-Mail Website
Guest Editor
1. Department of Microbiology and Immunology, Faculty of Medicine, CHU de Quebec and Laval University, Quebec City, QC G1V 4G2, Canada
2. Global Urgent and Advanced Research and Development, Batiscan City, QC G0X 1A0, Canada
Interests: antibody gene therapy; infectious diseases

Special Issue Information

Dear Colleagues,

Therapeutic antibodies have revolutionized modern medicines, notably the treatment of cancer, autoimmune disorders and infectious diseases. Despite their clinically proven efficacy, the use of therapeutic antibody is mainly limited to richer countries. Indeed, an estimated 80% of therapeutic antibodies are administered in North America and Europe alone.

The prohibitive costs of therapeutic antibodies and to a lower extent the need for intravenous administration have been hurdles to their wide-spread use. Various solutions are currently in pre-clinical phases of development. Notably, antibody gene therapy in which the nucleotide sequence of therapeutic antibodies, rather than proteins, are administered could help reduce the cost of antibody therapy. Sub-cutaneous formulation have also been developed to facilitate the administration of therapeutic antibodies.

This issue will focus on research encompassing novel therapeutic antibodies against infectious diseases. Submissions, on innovative work that could facilitate the broader use of therapeutic antibody globally, are also encouraged.

Dr. Hugues Fausther-Bovendo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • therapeutic antibodies
  • infectious diseases
  • mAb gene therapy
  • delivery routes
  • affordability

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

17 pages, 788 KiB  
Review
Recent Advancements in AAV-Vectored Immunoprophylaxis in the Nonhuman Primate Model
by Elena S. B. Campbell, Melanie M. Goens, Wenguang Cao, Brad Thompson, Leonardo Susta, Logan Banadyga and Sarah K. Wootton
Biomedicines 2023, 11(8), 2223; https://doi.org/10.3390/biomedicines11082223 - 8 Aug 2023
Cited by 1 | Viewed by 1992
Abstract
Monoclonal antibodies (mAbs) are important treatment modalities for preventing and treating infectious diseases, especially for those lacking prophylactic vaccines or effective therapies. Recent advances in mAb gene cloning from naturally infected or immunized individuals has led to the development of highly potent human [...] Read more.
Monoclonal antibodies (mAbs) are important treatment modalities for preventing and treating infectious diseases, especially for those lacking prophylactic vaccines or effective therapies. Recent advances in mAb gene cloning from naturally infected or immunized individuals has led to the development of highly potent human mAbs against a wide range of human and animal pathogens. While effective, the serum half-lives of mAbs are quite variable, with single administrations usually resulting in short-term protection, requiring repeated doses to maintain therapeutic concentrations for extended periods of time. Moreover, due to their limited time in circulation, mAb therapies are rarely given prophylactically; instead, they are generally administered therapeutically after the onset of symptoms, thus preventing mortality, but not morbidity. Adeno-associated virus (AAV) vectors have an established record of high-efficiency in vivo gene transfer in a variety of animal models and humans. When delivered to post-mitotic tissues such as skeletal muscle, brain, and heart, or to organs in which cells turn over slowly, such as the liver and lungs, AAV vector genomes assume the form of episomal concatemers that direct transgene expression, often for the lifetime of the cell. Based on these attributes, many research groups have explored AAV-vectored delivery of highly potent mAb genes as a strategy to enable long-term expression of therapeutic mAbs directly in vivo following intramuscular or intranasal administration. However, clinical trials in humans and studies in nonhuman primates (NHPs) indicate that while AAVs are a powerful and promising platform for vectored immunoprophylaxis (VIP), further optimization is needed to decrease anti-drug antibody (ADA) and anti-capsid antibody responses, ultimately leading to increased serum transgene expression levels and improved therapeutic efficacy. The following review will summarize the current landscape of AAV VIP in NHP models, with an emphasis on vector and transgene design as well as general delivery system optimization. In addition, major obstacles to AAV VIP, along with implications for clinical translation, will be discussed. Full article
(This article belongs to the Special Issue Therapeutic Antibodies against Infectious Diseases)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop